15:56:16 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-22 Kvartalsrapport 2024-Q3
2024-07-07 Kvartalsrapport 2024-Q2
2024-05-08 Bonusutdelning BIOG B 5
2024-05-08 Ordinarie utdelning BIOG B 1.90 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-07 Bokslutskommuniké 2023
2023-10-20 Kvartalsrapport 2023-Q3
2023-07-21 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning BIOG B 1.45 SEK
2023-05-08 Bonusutdelning BIOG B 1.45
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-02-03 Bokslutskommuniké 2022
2022-10-21 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-18 Split BIOG B 1:5
2022-05-09 Bonusutdelning BIOG B 11.29
2022-05-09 Ordinarie utdelning BIOG B 3.63 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-04 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning BIOG B 3.41 SEK
2021-05-06 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-11-25 Extra Bolagsstämma 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-08 Ordinarie utdelning BIOG B 3.75 SEK
2020-05-07 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-06 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-05-09 Bonusutdelning BIOG B 5.95
2019-05-09 Ordinarie utdelning BIOG B 4.05 SEK
2019-02-07 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-08-17 Kvartalsrapport 2018-Q2
2018-04-26 Ordinarie utdelning BIOG B 4.31 SEK
2018-04-26 Bonusutdelning BIOG B 4.69
2018-04-25 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-08 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-04 Bonusutdelning BIOG B 4.34
2017-05-04 Ordinarie utdelning BIOG B 3.16 SEK
2017-05-03 Kvartalsrapport 2017-Q1
2017-05-03 Årsstämma 2017
2017-02-10 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-11 Bonusutdelning BIOG B 1.97
2016-05-11 Ordinarie utdelning BIOG B 3.03 SEK
2016-05-10 Kvartalsrapport 2016-Q1
2016-05-10 Årsstämma 2016
2016-03-18 Extra Bolagsstämma 2016
2016-02-12 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-08 Bonusutdelning BIOG B 1.54
2015-05-08 Ordinarie utdelning BIOG B 3.46 SEK
2015-05-07 Kvartalsrapport 2015-Q1
2015-05-07 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-10-22 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-05-07 Bonusutdelning BIOG B 3.65
2014-05-07 Ordinarie utdelning BIOG B 3.35 SEK
2014-05-06 Årsstämma 2014
2014-05-06 Kvartalsrapport 2014-Q1
2014-02-12 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-04-29 Ordinarie utdelning BIOG B 4.15 SEK
2013-04-29 Bonusutdelning BIOG B 5.85
2013-04-26 Kvartalsrapport 2013-Q1
2013-04-26 Årsstämma 2013
2013-04-26 Analytiker möte 2013
2013-02-08 Bokslutskommuniké 2012
2012-10-23 Analytiker möte 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-09 Ordinarie utdelning BIOG B 1.26 SEK
2012-05-09 Bonusutdelning BIOG B 2.74
2012-05-08 Kvartalsrapport 2012-Q1
2012-05-08 Årsstämma 2012
2012-02-10 Bokslutskommuniké 2011
2011-11-17 Kapitalmarknadsdag 2011
2011-10-25 Kvartalsrapport 2011-Q3
2011-05-11 Ordinarie utdelning BIOG B 0.92 SEK
2011-05-11 Bonusutdelning BIOG B 1.08
2011-05-10 Kvartalsrapport 2011-Q1
2011-05-10 Årsstämma 2011
2011-02-11 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-17 Kvartalsrapport 2010-Q2
2010-05-07 Bonusutdelning BIOG B 0.6
2010-05-07 Ordinarie utdelning BIOG B 0.90 SEK
2010-05-06 Kvartalsrapport 2010-Q1
2010-02-22 Bokslutskommuniké 2009
2009-10-22 Kvartalsrapport 2009-Q3
2009-08-18 Kvartalsrapport 2009-Q2
2009-04-23 Ordinarie utdelning BIOG B 0.40 SEK
2009-04-22 Årsstämma 1
2009-04-22 Kvartalsrapport 2009-Q1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
BioGaia är verksamma inom bioteknik. Bolaget utvecklar, marknadsför och säljer probiotiska produkter. Produkterna är huvudsakligen baserade på bakterien lactobacillus reuteri som har probiotiska effekter. Idag säljs bolagets produkter runtom den globala marknaden. Forskning och utveckling främjas via bolagets externa nätverk av forskningsinstitutioner och kliniker. Huvudkontoret ligger i Stockholm.
2021-08-12 08:00:00
Second quarter 2021
  • Net sales amounted to SEK 203.1 million (244.7), a decrease of 17% (excluding foreign exchange effects, -8%). The change in sales was affected by higher comparative figures since the corresponding period last year was positively affected by Covid-19 related inventory build-up at many of our customers.
  • Net sales in the Paediatrics segment reached SEK 161.1 million (199.2), a decrease of 19%.
  • Net sales in the Adult Health segment amounted to SEK 40.9 million (44.4), a decrease of 8%.
  • Operating expenses amounted to SEK 81.6 million (84.2), a decrease of 3%.
  • Operating profit decreased by 31% to SEK 69.2 million (100.2), which corresponds to an operating margin of 34% (41%)
  • Profit after tax was SEK 54.7 million (79.0), a decrease of 31%.
  • Earnings per share amounted to SEK 2.71 (4.52) before and after dilution.
  • Cash flow for the period was SEK -16.2 million (-38.7).
  • Cash and cash equivalents at 30 June 2021 amounted to SEK 1,468.9 million (242.5).
Key events in the second quarter of 2021
  • On 8 April, BioGaia announced that the company has signed an agreement with Minapharm Pharmaceuticals for exclusive rights to sell BioGaia Protectis drops in Egypt.
  • On 13 April, BioGaia announced that a randomised, double-blind, placebo-controlled study in children showed that a supplement of two L. reuteri strains significantly reduced fever and pain in children with upper respiratory tract infections.
  • On 20 May, the company announced that BioGaia's products will be sold under the BioGaia brand in Finland.
First half 2021
  • Net sales amounted to SEK 405.1 million (427.5), a decrease of 5% (excluding foreign exchange effects, +5%).
  • Net sales in the Paediatrics segment reached SEK 322.8 million (341.6), a decrease of 6%.
  • Net sales in the Adult Health segment amounted to SEK 79.6 million (84.5), a decrease of 6%.
  • Operating expenses amounted to SEK 162.6 million (161.6), an increase of 1%. Operating expenses included costs of evaluation of acquisition candidates of SEK 2.5 million and restructuring costs of SEK 7.5 million. Excluding these costs, operating expenses amounted to SEK 152.6 million, a decrease of 6%.
  • Operating profit decreased by 15% to SEK 133.5 million (155.9), which corresponds to an operating margin of 33% (36%). Profit after tax was SEK 105.1 million (120.8), a decrease of 13%.
  • Earnings per share amounted to SEK 5.21 (6.91) before and after dilution.
  • Cash flow for the period was SEK 1.1 million (28.7).
Key events after the end of the second quarter
  • On 2 July, BioGaia announced that the company had become the owner of 100% of the shares in MetaboGen. Previously, BioGaia owned 92% of the shares. The purchase price amounted to SEK 11.4 million and is recognised in the half-year financial statements as a current liability to be settled in July.

CEO's comment

"Currently and for over a year now, the Covid-19 situation continues to impact our sales and earnings. During the first and especially the second quarter of last year many of our distributors built up inventories to avoid being affected by the anticipated delivery difficulties connected to the Covid-19 crisis. This has resulted in greater fluctuations than normal in our sales as well as between our regions. Furthermore, the still relatively strong Swedish krona has also affected our earnings.  

In the second quarter of 2020 we therefore achieved sales of SEK 245 million, our best-ever quarter. Under previous normal conditions, we consider a quarter with sales in excess of SEK 200 million to be a good quarter. In the second quarter of this year we landed at SEK 203 million (a decrease of 17% and excluding foreign exchange effects, -8%) despite the fact that the first quarter this year was relatively strong with orders from China that were delivered in the final days of March instead of in the second quarter.As usual and especially in view of the impact of the Covid situation on inventory and sales, the half-year figures are more relevant and here we see organic growth of 5%. We are not satisfied with this but at any rate it is heading in the right direction."

For more information and the entire CEO comment, see attached interim management statement.
Teleconference: Investors, analysts and the media are invited to take part in a teleconference on the interim management statement to be held today 12 August 2021 at 09:30 CET with CEO Isabelle Ducellier and CFO Alexander Kotsinas. To participate in the teleconference, please see Financialhearings.com (https://financialhearings.com/event/13237) for telephone numbers. The teleconference can also be followed here (https://tv.streamfabriken.com/biogaia-q2-2021).

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the CEO, on 12-08-2021 08:00 CET.